Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | AKT2 | P31751 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 15/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1746576 | 0.88 | MKNK1 (0.49) | AKT1AKT2PDE4APDE4BPDE4C | |
| SCHEMBL3355854 | 0.81 | MKNK1 (0.39) | AKT1AKT2PDE4APDE4BPDE4C | |
| SCHEMBL456971 | 0.76 | MKNK1 (0.37) | AKT1AKT2PDE4APDE4BPDE4C | |
| SCHEMBL22189658 | 0.75 | PDE4D (0.61) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1745964 | 0.73 | PDE4A (0.48) | AKT1AKT2PDE4APDE4BPDE4C | |
| SCHEMBL31704447 | 0.70 | KDM4E (0.55) | AKT1AKT2 | |
| SCHEMBL361368 | 0.68 | AKT1 (0.49) | AKT1AKT2 | |
| SCHEMBL4710579 | 0.68 | MKNK1 (0.49) | PDE4APDE4BPDE4CPDE4DRIPK3 | |
| SCHEMBL2674833 | 0.67 | ALDH1A1 (0.41) | AKT1AKT2PDE4A | |
| SCHEMBL2068562 | 0.67 | PDE4B (0.35) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370769-B2 | TRPC5 inhibitors and methods of using same | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2022-06-28 | — | — | US | disclosed |
| US-20200216411-A1 | TRPC5 INHIBITORS AND METHODS OF USING SAME | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216411-A1 | TRPC5 INHIBITORS AND METHODS OF USING SAME | TRPC5, TRPC1, TRPC7 | AKT1 2848/4885AKT2 2508/4885PDE4A 1673/4885 |
| US-11370769-B2 | TRPC5 inhibitors and methods of using same | TRPC5, TRPC1, TRPC7 | AKT1 2848/4885AKT2 2508/4885PDE4A 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.